About the client
Instem plc is a leading supplier of software solutions to the global early development healthcare market. Its solutions are used by organisations, mainly in the pharmaceutical R&D sector, for data collection, management and analysis.
For more than 400 clients around the world, Instem supplies breakthrough technology and services that help efficiently access, capture, manage and enrich a wide array of data.
About the deal
Rickitt Mitchell negotiated a deal that was heavily weighted towards a performance based earn-out. The deal was structured so that the consideration was satisfied through a mixture of cash and Instem shares.
Headquartered in the UK, and with employees in the US and Europe, Logos is a leading provider of world-class clinical trial solutions to pharmaceutical and clinical research organisations.
The acquisition represents a strategic move by Instem into the early phase clinical market.
“This earnings-enhancing acquisition is an important part of our growth strategy. We are delighted that the talented team at Logos will be joining the Instem group and we look forward to working together to provide valuable automation tools to enable our clients to bring new products to market quickly and cost effectively.”Phil Reason | CEO | Instem plc